Latest Revenue Growth News

WT Financial Group (ASX, WTL) reported a 20.5% rise in FY2025 net profit after tax to $4.6 million, driven by strong revenue growth and operational leverage. The company declared a fully-franked dividend of 0.7 cents per share, underpinned by its expanding B2B financial advice network and proprietary risk management framework.

FINEOS Corporation Holdings PLC reports solid half-year growth with rising subscription revenue and improved margins, while navigating currency challenges. The company remains confident in achieving positive free cash flow for FY25 and advancing its AI and cloud strategies.

FINEOS Corporation Holdings plc reported a 4.2% increase in revenue to €67.1 million for H1 2025, alongside a significant 76% reduction in losses, driven by subscription growth and operational efficiencies.

Titomic Limited reported a 22.5% increase in revenue to $9.43 million for FY2025 but saw losses soar by over 67%, highlighting ongoing financial challenges despite growth.

Clever Culture Systems Ltd has reported a remarkable 288% jump in revenue to $6.63 million for the year ended June 2025, turning around from a loss to a net profit of $1.68 million, buoyed by strong product sales and government support.

De.mem Limited has reported a record half-year performance for 2025, with revenue up 20% and its first positive adjusted EBITDA, driven by strong recurring revenues and strategic acquisitions.

Dicker Data Ltd reported a robust 15.7% increase in gross revenue for H1 FY25, driven by AI deployments and accelerated PC refresh cycles. The company also provided confident FY25 guidance amid strategic moves into AI ecosystems and cybersecurity.

Resimac Group Ltd reported a stable FY25 net profit after tax of $34.6 million and declared a fully franked final dividend of 3.5 cents per share, maintaining its steady financial footing amid modest revenue growth.

Farm Pride Foods Ltd has reported a remarkable 384% increase in net profit for the financial year ending June 2025, despite revenues remaining virtually unchanged. The company’s financial health shows signs of strengthening, though no dividends were declared.

Vitasora Health reported a sharp rise in losses and operating cash outflows for FY2025, despite achieving significant cost savings from its Orb Health acquisition. The company faces a material uncertainty over its ability to continue as a going concern.

Clinuvel Pharmaceuticals has reported a robust financial year ending June 2025, marked by solid revenue growth and sustained profitability, while advancing its clinical pipeline and maintaining a strong balance sheet.

Clinuvel Pharmaceuticals has reported its ninth consecutive year of revenue and profit growth, driven by strong sales of SCENESSE® and strategic investment in vitiligo clinical trials. The company also declared its eighth consecutive dividend, underscoring financial resilience.